You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameChorionic Gonadotropin (Recombinant)
Accession NumberDB00097  (BTD00034, BIOD00034)
TypeBiotech
GroupsApproved
DescriptionRecombinant human chorionic gonadotropin with 2 subunits, alpha = 92 residues, beta = 145 residues, each with N-and O-linked carbohydrate moieties linked to ASN-52 and ASN-78 (on alpha subunit) and ASN-13, ASN-30, SER-121, SER-127, SER-132 and SER-138 (on beta subunit). The primary structure of the alpha-chain of r-hCG is identical to that of the alpha-chain of hCG, FSH and LH.
Protein structureDb00097
Related Articles
Protein chemical formulaC1105H1770N318O336S26
Protein average weight25719.7 Da
Sequences
>Alpha chain
APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCC
VAKSYNRVTVMGGFKVENHTACHCSTCYYHKS
>Beta chain
SKEPLRPRCRPINATLAVEKEGCPVCITVNTTICAGYCPTMTRVLQGVLPALPQVVCNYR
DVRFESIRLPGCPRGVNPVVSYAVALSCQCALCRRSTTDCGGPKDHPLTCDDPRFQDSSS
SKAPPPSLPSPSRLPGPSDTPILPQ
Download FASTA Format
Synonyms
CG-beta
Choriogonadotropin alpha
Choriogonadotropin beta chain precursor
Chorionic gonadotrophin beta subunit
hCG
r-HCG
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
OvidrelSolution250 mcgSubcutaneousEmd Serono, A Division Of Emd Inc., Canada2004-12-20Not applicableCanada
OvidrelSolution250 mcgSubcutaneousEmd Serono, A Division Of Emd Inc., Canada2013-05-28Not applicableCanada
OvitrelleInjection, solution250 microgramsSubcutaneousMerck Serono Europe Limited2001-02-02Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ProfasiSerono S.A.
Brand mixturesNot Available
SaltsNot Available
CategoriesNot Available
UNII6413W06WR3
CAS number177073-44-8
Pharmacology
IndicationFor the treatment of female infertility
Structured Indications Not Available
PharmacodynamicsChoriogonadotropin alfa is used to treat female infertility, Choriogonadotropin alfa stimulates late follicular maturation and resumption of oocyte meiosis, and initiates rupture of the pre-ovulatory ovarian follicle. Ovidrel is an analogue of Luteinizing Hormone (LH) and binds to the LH/hCG receptor of the granulosa and theca cells of the ovary to effect these changes in the absence of an endogenous LH surge.
Mechanism of actionChoriogonadotropin alfa binds to the Follicle stimulating hormone receptor which results in ovulation in the absence of sufficient endogenous Luteinizing hormone.
TargetKindPharmacological actionActionsOrganismUniProt ID
Lutropin-choriogonadotropic hormone receptorProteinyesNot AvailableHumanP22888 details
Follicle-stimulating hormone receptorProteinyes
binder
HumanP23945 details
Related Articles
AbsorptionThe mean absolute bioavailability following a single subcutaneous injection to healthy female volunteers is about 40%.
Volume of distribution
  • 5.9 ± 1.0 L
Protein bindingNot Available
MetabolismNot Available
Route of eliminationOne-tenth of the dose is excreted in the urine.
Half lifeThe mean terminal half-life is about 29 ± 6 hours (initial half-life is 4.5 ± 0.5 hours).
Clearance
  • 0.29 +/- 0.04 L/h [healthy down-regulated females]
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug InteractionsNot Available
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Kayisli UA, Selam B, Guzeloglu-Kayisli O, Demir R, Arici A: Human chorionic gonadotropin contributes to maternal immunotolerance and endometrial apoptosis by regulating Fas-Fas ligand system. J Immunol. 2003 Sep 1;171(5):2305-13. [PubMed:12928375 ]
  2. Askling J, Erlandsson G, Kaijser M, Akre O, Ekbom A: Sickness in pregnancy and sex of child. Lancet. 1999 Dec 11;354(9195):2053. [PubMed:10636378 ]
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelDownload (97.1 KB)
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic SciencePolycystic Ovaries Syndrome1
0CompletedScreeningInfertilities1
0CompletedTreatmentSpontaneous Triggering of Ovulation vs. Administration of Human Chorionic Gonadotropin in Patients Undergoing IUI1
1, 2CompletedTreatmentHealthy Males1
1, 2RecruitingSupportive CareGraft Versus Host Disease (GVHD)1
2CompletedTreatmentAssisted Reproductive Technology therapy / Infertilities1
2CompletedTreatmentFertility Agents, Female1
2CompletedTreatmentInfertilities1
2Not Yet RecruitingTreatmentInfertilities1
2Not Yet RecruitingTreatmentPituitary gonadotropin hypofunction1
2RecruitingTreatmentAzoospermia1
2RecruitingTreatmentTraumatic Brain Injury (TBI)1
2TerminatedTreatmentInfertilities / Ovulation induction therapy1
2TerminatedTreatmentOvulation induction therapy1
2TerminatedTreatmentStroke2
2WithdrawnTreatmentStroke1
3CompletedDiagnosticPolycystic Ovarian Syndrome1
3CompletedDiagnosticPolycystic Ovaries Syndrome1
3CompletedTreatmentAssisted Reproductive Techniques / Reproductive Technology, Assisted1
3CompletedTreatmentEmbryo Transfer / Luteal Hormone Supplementation in In-vitro Fertilization1
3CompletedTreatmentHyperovulation Induction for Assisted Reproduction Treatment1
3CompletedTreatmentHypogonadism1
3CompletedTreatmentHypogonadism / Hypogonadotropic Hypogonadism1
3CompletedTreatmentInfertilities4
3CompletedTreatmentPolycystic Ovarian Syndrome1
3Not Yet RecruitingTreatmentInfertilities1
3RecruitingPreventionCancer, Breast1
3RecruitingTreatmentInfertilities1
3RecruitingTreatmentOvulatory Dysfunction1
3SuspendedTreatmentSterility1
3WithdrawnTreatmentInfertilities1
4Active Not RecruitingBasic ScienceInfertilities / Subfertility1
4Active Not RecruitingTreatmentEndometrial Thickness / Pregnancy Outcomes1
4Active Not RecruitingTreatmentInfertilities1
4CompletedNot AvailableInfertilities / Premature Ovarian Failure (POF)1
4CompletedBasic ScienceControlled Ovarian Stimulation / Infertilities1
4CompletedTreatmentInfertile Women Undergoing Assisted Reproductive Technology (ART)1
4CompletedTreatmentInfertilities3
4CompletedTreatmentPregnancy1
4Not Yet RecruitingTreatmentInfertilities1
4RecruitingSupportive CareInfertilities2
4RecruitingTreatmentInfertilities / InVitro Fertilization1
4RecruitingTreatmentInfertilities3
4RecruitingTreatmentInfertilities / Polycystic Ovarian Syndrome1
4RecruitingTreatmentOvarian Hyperstimulation Syndrome2
4RecruitingTreatmentSupervision of Pregnancy Resulting From In-vitro Fertilization1
4TerminatedTreatmentAssisted Reproductive Technology therapy1
4TerminatedTreatmentHypogonadotropic Hypogonadism1
Not AvailableActive Not RecruitingTreatmentNatural Cycle in Vitro Fertilization (IVF)1
Not AvailableCompletedNot AvailableAssisted Reproductive Technology therapy1
Not AvailableCompletedNot AvailableInfertilities / Ovulation induction therapy1
Not AvailableCompletedDiagnosticHypogonadism / Spinal Cord Injuries (SCI)1
Not AvailableCompletedScreeningPolycystic Ovaries Syndrome1
Not AvailableCompletedTreatmentInfertilities3
Not AvailableEnrolling by InvitationDiagnosticEndometrial Receptivity / Ovarian Hyperstimulation Syndrome1
Not AvailableNot Yet RecruitingBasic ScienceBMI >30 kg/m2 / Hyperandrogenemia / Polycystic Ovaries Syndrome4
Not AvailableNot Yet RecruitingTreatmentInfertilities2
Not AvailableRecruitingNot AvailableLow Responders / Mild to Moderate Male Factor Infertility / Primary Infertility / Secondary Infertility1
Not AvailableRecruitingNot AvailablePolycystic Ovaries Syndrome1
Not AvailableRecruitingBasic ScienceBMI >30 kg/m2 / Hyperandrogenism / Polycystic Ovaries Syndrome1
Not AvailableRecruitingPreventionInfertility and at High Risk of OHSS1
Not AvailableRecruitingTreatmentAssisted Reproductive Technology therapy / Poor Responder1
Not AvailableRecruitingTreatmentInfertilities2
Not AvailableRecruitingTreatmentInfertilities / OHSS1
Pharmacoeconomics
Manufacturers
  • Emd serono inc
  • Ferring pharmaceuticals inc
  • App pharmaceuticals llc
  • Bel mar laboratories inc
  • Bristol myers squibb
  • Organon usa inc
Packagers
Dosage forms
FormRouteStrength
SolutionSubcutaneous250 mcg
Injection, solutionSubcutaneous250 micrograms
Prices
Unit descriptionCostUnit
Novarel 10000 unit/10ml Solution 1 Vial = 10ml118.55USD vial
Novarel 10000 unit vial113.99USD vial
Ovidrel 250 mcg/0.5ml Injectable 0.5ml Syringe93.22USD syringe
Pregnyl 10000 unit Solution60.7USD vial
Pregnyl 10000 unit vial57.23USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5767251 No1995-06-162015-06-16Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point55 °CForastieri, H., Ingham, K.C. J. Biol. Chem. 257:7976-7981 (1982)
hydrophobicity-0.258Not Available
isoelectric point8.61Not Available
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Luteinizing hormone receptor activity
Specific Function:
Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase.
Gene Name:
LHCGR
Uniprot ID:
P22888
Molecular Weight:
78642.01 Da
References
  1. Bodek G, Vierre S, Rivero-Muller A, Huhtaniemi I, Ziecik AJ, Rahman NA: A novel targeted therapy of Leydig and granulosa cell tumors through the luteinizing hormone receptor using a hecate-chorionic gonadotropin beta conjugate in transgenic mice. Neoplasia. 2005 May;7(5):497-508. [PubMed:15967102 ]
  2. Gromoll J, Wistuba J, Terwort N, Godmann M, Muller T, Simoni M: A new subclass of the luteinizing hormone/chorionic gonadotropin receptor lacking exon 10 messenger RNA in the New World monkey (Platyrrhini) lineage. Biol Reprod. 2003 Jul;69(1):75-80. Epub 2003 Feb 19. [PubMed:12606382 ]
  3. Lin W, Bernard MP, Cao D, Myers RV, Kerrigan JE, Moyle WR: Follitropin receptors contain cryptic ligand binding sites. Mol Cell Endocrinol. 2007 Jan 2;260-262:83-92. Epub 2006 Oct 23. [PubMed:17059863 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
binder
General Function:
G-protein coupled peptide receptor activity
Specific Function:
Receptor for follicle-stimulating hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Induces cAMP production through the activation of PI3K-AKT and SRC-ERK1/2 signaling pathways.
Gene Name:
FSHR
Uniprot ID:
P23945
Molecular Weight:
78264.07 Da
References
  1. Jameson JL: Inherited disorders of the gonadotropin hormones. Mol Cell Endocrinol. 1996 Dec 20;125(1-2):143-9. [PubMed:9027352 ]
  2. Lin W, Bernard MP, Cao D, Myers RV, Kerrigan JE, Moyle WR: Follitropin receptors contain cryptic ligand binding sites. Mol Cell Endocrinol. 2007 Jan 2;260-262:83-92. Epub 2006 Oct 23. [PubMed:17059863 ]
  3. Tao YX, Segaloff DL: Follicle stimulating hormone receptor mutations and reproductive disorders. Prog Mol Biol Transl Sci. 2009;89:115-31. doi: 10.1016/S1877-1173(09)89005-4. Epub 2009 Oct 7. [PubMed:20374735 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23